Research Analysts Issue Forecasts for ORKA FY2025 Earnings

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Investment analysts at Wedbush decreased their FY2025 earnings per share (EPS) estimates for Oruka Therapeutics in a report issued on Thursday, November 13th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($1.90) per share for the year, down from their prior forecast of ($1.70). Wedbush has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.14) EPS, FY2027 earnings at ($2.46) EPS, FY2028 earnings at ($3.15) EPS and FY2029 earnings at ($3.79) EPS.

A number of other equities analysts have also weighed in on ORKA. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Guggenheim initiated coverage on shares of Oruka Therapeutics in a report on Monday, October 27th. They issued a “buy” rating and a $60.00 price objective for the company. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a research report on Thursday. They set a “buy” rating and a $45.00 price objective for the company. Finally, HC Wainwright decreased their target price on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.14.

Oruka Therapeutics Stock Up 2.7%

ORKA opened at $27.08 on Monday. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $29.98. The company has a 50-day moving average price of $22.60 and a 200 day moving average price of $16.28. The company has a market cap of $1.12 billion, a PE ratio of -9.64 and a beta of -0.30.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.01.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. bought a new stake in Oruka Therapeutics during the third quarter worth approximately $39,000. Russell Investments Group Ltd. acquired a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $43,000. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $28,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at $31,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after buying an additional 2,306 shares during the period. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.